BrightEdge — 2026 Investments
2 investments dated 2026 · listed companies and verified rows first · show all
CellCentricLate Stage · May 2026 · $220M
TippingPoint Biosciencestippingpointbiosciences.cominSeed · Mar 2026 · $4.5M
TippingPoint Biosciences is a therapeutics company developing a drug discovery platform that targets unstructured regions in chromatin proteins to treat diseases caused by dysfunctional genome chromatin packaging, with a focus on cancer.
BiotechDeep TechHealthtechSan Francisco, US
Laura Hsieh(Founder & CEO)in
Co-investorsFREEFLOW
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.